Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.83)
# 1,877
Out of 5,008 analysts
45
Total ratings
37.14%
Success rate
53.09%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $14.12 | +6.23% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.24 | +748.21% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $14.16 | +111.86% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.31 | +1,579.39% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $7.57 | +217.04% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $22.63 | +452.36% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $4.76 | +278.15% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.25 | +484.62% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.16 | - | 1 | Oct 1, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $211.04 | -62.49% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $57.75 | +168.40% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $11.26 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $8.76 | +185.39% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $5.72 | +31,368.53% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $33.11 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.72 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.14 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $5.13 | +29,139.77% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $2.01 | +44,676.12% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.22 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $11.29 | +1,361.47% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $102.17 | +120.22% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.53 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.56 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $14.12
Upside: +6.23%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.24
Upside: +748.21%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $14.16
Upside: +111.86%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.31
Upside: +1,579.39%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $7.57
Upside: +217.04%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $22.63
Upside: +452.36%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.76
Upside: +278.15%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.25
Upside: +484.62%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.16
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $211.04
Upside: -62.49%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $57.75
Upside: +168.40%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $11.26
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $8.76
Upside: +185.39%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $5.72
Upside: +31,368.53%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $33.11
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.72
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.14
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $5.13
Upside: +29,139.77%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $2.01
Upside: +44,676.12%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $9.22
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $11.29
Upside: +1,361.47%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $102.17
Upside: +120.22%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.53
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.56
Upside: -